CNS Drugs

Article	Citations
Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study	160
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Ran	115
Correction: Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta‑Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder	92
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?	92
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“	71
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study	65
The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies	61
Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind	61
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives	59
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials	58
The Use of Ketamine for the Treatment of Anhedonia in Depression	54
The State of Synthetic Cannabinoid Medications for the Treatment of Pain	54
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany	53
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies	52
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients	52
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use	51
Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder	49
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology	49
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial	43
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain	39
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis	38
Alternative Routes of Administration of Clozapine	38
Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients	38
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies	37
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia	36

Pharmacotherapy for Frontotemporal Dementia	35
FcRn Inhibitor Therapies in Neurologic Diseases	33
COMT Inhibitors in the Management of Parkinson’s Disease	32
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature	31
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis	31
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis	31
Psychotropic Drugs Reemerging as Headache Medicines	31
Over the Counter Supplements for Memory: A Review of Available Evidence	30
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis	29
Unmet Needs in Psychodermatology: A Narrative Review	27
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis	27
Current Landscape of NTRK Inhibition for Pediatric CNS Tumors	27
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex	27
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	26
Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	25
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem	25
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes	25
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study	25
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders	24
Pharmacotherapy to Manage Central Post-Stroke Pain	24
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets	22
Risdiplam: A Review in Spinal Muscular Atrophy	21
Idiopathic Hypersomnia: Neurobiology, Diagnosis, and Management	20
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio	20
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	20
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease	20
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs	20
Correction to: Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life‑Sustaining Therapies: A Systematic Review	19
New and Emerging Drug and Gene Therapies for Friedreich Ataxia	19
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies	19
Daridorexant in Insomnia Disorder: A Profile of Its Use	19
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study	19
Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use	18
Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?	18
Author’s Reply to Liu et al.: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	18
Comment on: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	18
Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022	18
Correction to: The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond	18
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	17
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation	17
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial	17
Authors’ Reply to Chevle et al.: Comment on “Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage”	17
Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively	17
Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”	16
Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis	15
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review	15
Acknowledgement to Referees	15
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis	14
Effects of One-Year Anti-seizure Treatment with Add-On Cenobamate on Bone Density and Bone Turnover in Adults with Drug-Resistant Focal Epilepsy: An Observational Study	14
Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis	14

Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis	14
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	14
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study	14
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study	14
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders	14
Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression	13
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-	13
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis	13
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine	13
Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care	13
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine N	13
Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach	13
Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study	12
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial	12
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials	12
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controll	12
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention	12
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study	12
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial	12
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data	12
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder	11
Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management	11
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)	11
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations	11
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy	11
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression	11
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine	11
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts	11
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial	11
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update	11
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment	11
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis	10
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status	10
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders	10
Potential Role of Curcumin for the Treatment of Major Depressive Disorder	10
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants	10
Correction to: Effect of Enzyme‑Inducing Antiseizure Medications on the Risk of Sub‑Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study	10
The Options for Neuraxial Drug Administration	10
Authors’ Reply to Ulrich: Comment on ‘Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively’	9
Treatment of Seizures in People with Intellectual Disability	9
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males	9
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance	9
Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis	9
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy	9
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience	9
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”	9
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy	9
CNS Viral Infections—What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches	9
Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development	8
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinic	8
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hype	8
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis	8
Treatment Outcomes of Newly Diagnosed Epilepsy: A Systematic Review and Meta-analysis	8
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations	8
Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis	8
Clonazepam Loading Dose in Status Epilepticus: Is More Always Better?	8
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study	8
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat	8
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review	8
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adult	8
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis	7
Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)	7
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Repo	7
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease	7
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study	7
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing	7
Authors’ Reply to Pereira Ribeiro et al.: Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta‑Analysis”	7
Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures	7
Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials	7
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receivin	7
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder	7
Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients	7
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review	7
Targeting Pannexin-1 Channels: Addressing the ‘Gap’ in Chronic Pain	7
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk	6
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study	6
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	6
Nusinersen: A Review in 5q Spinal Muscular Atrophy	6
Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study	6
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively	6

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies	6
Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center	6
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia	6
Rett Syndrome: The Emerging Landscape of Treatment Strategies	6
Correction to: Daridorexant in Insomnia Disorder: A Profile of Its Use	6
Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis	6
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	5
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications	5
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research	5
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease	5
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys	5
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use	5
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis	5
Antiseizure Drugs and Movement Disorders	5
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder	5
Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists	5
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis	4
Pharmacological Management of Borderline Personality Disorder and Common Comorbidities	4
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome	4
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score	4
Treatment Options in Refractory Autoimmune Encephalitis	4
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder	4
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies	4
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research	4
Pharmacological Management of Apathy in Dementia	4
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval	4
Dextromethorphan/Bupropion: First Approval	4
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation	4
Comment on “Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage”	4